DIRS.INFO The most relevant business & tech news

Credit Suisse's investment bankers are not waiting around to find out if UBS will give them jobs. UBS executives have pulled no punches when discussing the future of Credit Suisse's investment banking teams and trading desks. Jeff CohenA two-decade Credit Suisse veteran, Cohen heads up Credit Suisse's leveraged and acquisition finance business from New York. Previously, Cohen was Credit Suisse's head of global credit products and global head of leveraged finance capital markets. Marco SuperinaA Credit Suisse veteran since 1997, Superina heads Credit Suisse's M&A efforts in the firm's native Switzerland.

☆ GSK's Race to Bring an RSV Vaccine to Market
▼ + stars: | 2023-04-04 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailGSK's Race to Bring an RSV Vaccine to MarketThe race to bring the world's first respiratory syncytial virus (RSV) vaccine to market is underway, with GSK first out of the gate for FDA regulatory review this May. But competitors, including Pfizer, Sanofi and AstraZeneca, are also angling for a share of this estimated $10 billion dollar market.

If successful, Amgen would claim ownership of all antibodies that inhibit the PCSK9 protein, the mechanism of action for both Repatha and Praluent. Other companies could then do the same with their own antibody treatments in other disease areas. The case might also affect newer technologies used in medicine, such as CRISPR gene editing and messenger RNA, she said. A Washington, D.C.-based federal appeals court that covers U.S. patent cases invalidated Amgen's patent claiming ownership of all PCSK9 inhibitors as a whole in 2021. Amgen sued Sanofi and Regeneron in 2014.

☆ Regeneron and Sanofi Look for Billions From COPD Drug
▼ + stars: | 2023-03-25 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Dupixent was approved for eczema in 2017. Chronic obstructive pulmonary disease is the third-highest cause of death globally. Yet, despite its high death toll, it lacks great treatment options, and no new approaches have been approved in more than a decade. That is partly because it is a complex disease with different clinical characteristics that vary by patient, making it harder for companies to succeed in clinical trials. But there is a huge opportunity for drug companies that do come along with demonstrably good results.

Check out the companies making headlines in midday trading. GameStop -- The famed meme stock gained 2.5% in midday trading. The bank stock had been down about 14% after the bank's credit default swaps jumped without an apparent catalyst. Wells Fargo and JPMorgan — Shares of commercial bank giants were lower in midday trading, with Wells Fargo pulling back 2.3% while JPMorgan fell 2.2%. Activision Blizzard and Microsoft — Shares jumped 5% after the U.K. Competiton and Markets Authority dropped some of its concerns with the potential purchase of the company by Microsoft.

☆ Jefferies says Regeneron's Dupixent drug could drive shares 15% higher
▼ + stars: | 2023-03-24 | by ( Samantha Subin | ) www.cnbc.com time to read: +1 min

Regeneron 's Dupixent drug could serve as the next big catalyst for shares of the pharmaceutical company, according to Jefferies. REGN YTD mountain Regeneron shares so far this year A study released Thursday indicated that Dupixent, created with Sanofi, showed promise as a treatment for patients with COPD. Broken down, the data showed Dupixent reduced some moderate or severe acute exacerbations of COPD by 30%, compared with a placebo over a 52-week period. Tewari also views Eylea as another upside driver for shares as Wall Street gains more clarity on the drug. Shares of Regeneron have been on a tear in 2023, up 11% after gaining 14% during 2022's market rout.

The trial will be the first test of how Zantac cancer claims will fare before a jury. GSK said in a statement it disagreed with the ruling and would defend the case at trial. Originally marketed by a forerunner of GSK, it was later sold successively to Pfizer (PFE.N), Boehringer Ingelheim and finally Sanofi (SASY.PA). While NDMA is found in low levels in food and water, it is known to cause cancer in larger amounts. Analysts said it was not surprising that Grillo ruled differently from the federal court because California's courts are known to be friendlier to plaintiffs.

☆ Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data
▼ + stars: | 2023-03-23 | by ( Ludwig Burger Jubabu | Ludwig Burger | ) www.reuters.com time to read: +4 min

Sanofi and Regeneron said in a statement on Thursday a Phase III trial involving 939 current or former smokers also showed improvements in lung function, quality of life and COPD respiratory symptoms. JP Morgan analyst Richard Vosser said the trial update had "blow-out data" in store for investors, and that market consensus for 2027 Dupixent sales of 15.7 billion euros would likely be topped-up by between 1 and 2 billion euros. The anti-inflammatory drug accounted for 8.3 billion euros, or more than 19% of the French group's overall sales of 43 billion euros, last year. Sanofi reports combined global Dupixent sales from its alliance with Regeneron. Sanofi and Regeneron on Tuesday announced the European Commission had approved Dupixent to treat severe atopic dermatitis in young children.

☆ Pharma delivers, for others
▼ + stars: | 2023-03-23 | by ( ) www.reuters.com time to read: +2 min

The progressive lung disease, which commonly crops up in heavy smokers, is the third biggest cause of death globally. A 30% reduction in exacerbations and significant lung function improvement means the drug should spin more profit. Deloitte estimates projected returns on drug development for the biggest pharma firms were 1.2% last year. Writ large, the world might be getting too good of a bargain. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

☆ Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD
▼ + stars: | 2023-03-23 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Shares of Sanofi and Regeneron both jumped by more than 6% on Thursday after the pharmaceutical companies released promising data showing their jointly developed asthma drug Dupixent also shows promise in treating COPD patients. New data from a phase three clinical trial shows Dupixent reduced bad bouts of chronic obstructive pulmonary disease, or COPD, by 30% compared with a placebo over 52 weeks. The trial enrolled COPD patients with type 2 inflammation — an allergic response that can result in decreased lung function. The companies said a second phase three trial of Dupixent in COPD is ongoing, with data expected in 2024. He added that J.P. Morgan expects to see new COPD patients adding $1.5 billion to $2 billion in new sales for Dupixent.

☆ Stocks making the biggest moves midday: Netflix, Block, Snap, KB Home and more
▼ + stars: | 2023-03-23 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

Check out the companies making the biggest moves midday:Netflix — The streaming giant's stock climbed 8.5% following a report from YipitData that said the company's gross additions in Canada have improved. Block — Shares plunged 14% after short seller Hindenburg Research announced its latest position in the stock. The firm alleges that Block facilitates fraud and described the company's internal systems as a "Wild West" approach to compliance. Meta Platforms , Snap — The social media stocks moved higher as TikTok CEO Shou Zi Chew testified before the House Energy and Commerce Committee. KB Home — Shares rallied 8.8% after the homebuilder's fiscal first-quarter earnings beat expectations.

☆ Sanofi, Regeneron's Dupixent shows promise as 'smoker's lung' drug
▼ + stars: | 2023-03-23 | by ( Ludwig Burger Jubabu | Ludwig Burger | ) www.reuters.com time to read: +3 min

In a late stage trial Dupixent, jointly developed with Regeneron (REGN.O), led to a 30% reduction in moderate or severe acute exacerbations of chronic obstructive pulmonary disease (COPD), a potentially deadly disease marked by progressive lung function decline. Sanofi previously forecast Dupixent would generate up to 13 billion euros ($14.2 billion) in sales in its best year as it seeks to widen its use across several inflammatory conditions. The anti-inflammatory drug accounted for 8.3 billion euros, or more than 19%, of the French group's overall sales of 43 billion euros last year. Sanofi reports combined global Dupixent sales from its alliance with Regeneron. Dupixent was also approved by the EC to treat eosinophilic esophagitis, a condition that damages the esophagus, in January.

☆ Vaccine makers prep bird flu shot for humans 'just in case'; rich nations lock in supplies
▼ + stars: | 2023-03-20 | by ( Jennifer Rigby | Thomson Reuters | Jen Reports On Health Issues Affecting People Around The World | ) www.reuters.com time to read: +5 min

There has also been a push among companies to develop a bird flu vaccine for poultry, a market potentially far larger than that for humans. Many countries' pandemic plans say flu shots should go first to the most vulnerable while supply is limited. The agreements include six of the largest seasonal flu manufacturers, such as GSK, Sanofi and CSL Seqirus, the WHO said. NEW APPROACHESIn a pandemic, vaccine manufacturers would shift production of seasonal flu vaccines and instead make shots tailored to the new outbreak when needed. The results will be closely watched, as the data on Moderna’s seasonal flu candidate was mixed.

☆ Morning Bid: Support for troubled banks calms markets
▼ + stars: | 2023-03-17 | by ( ) www.reuters.com time to read: +2 min

Asian stock markets clawed back 1.7% after after a 2.7% fall to more than three month lows since Monday. What seems to have changed is the guidance for rate hikes though many policymakers had suggested in recent weeks that sizeable increases were warranted. On Friday, final CPI data for the eurozone is due in a thin calendar for economic data releases. Citing people with knowledge of the matter, Bloomberg News reported that UBS Group and Credit Suisse are opposed to a forced merger. Key developments that could influence markets on Friday:Europe economic data: Eurozone final Feb CPI, Q4 labour costsU.S. economic data: University of Michigan surveyReporting by Anshuman Daga; Editing by Simon Cameron-MooreOur Standards: The Thomson Reuters Trust Principles.

☆ Diabetes Drug Giant Sanofi Cuts Insulin Prices by Up to 78%
▼ + stars: | 2023-03-16 | by ( Jared S. Hopkins | ) www.wsj.com time to read: 1 min

Sanofi plans to take a 78% list-price cut on its most widely used insulin in the U.S., joining other drugmakers facing criticism of insulin prices. French drugmaker Sanofi SA said it would cut the price of some of its insulin products by as much as 78% in the U.S., joining other big pharmaceutical companies facing pressure to reduce the cost of diabetes treatments. Sanofi plans to take a 78% list-price reduction on Lantus, the company’s most widely used insulin in the U.S., and a 70% cut on its Apidra product starting in January 2024, the company said Thursday.

☆ Sanofi to cut price of its most-prescribed insulin by 78% in US
▼ + stars: | 2023-03-16 | by ( ) www.reuters.com time to read: 1 min

March 16 (Reuters) - Sanofi SA (SASY.PA) said on Thursday it would cut U.S. list prices by 78% for its most-prescribed insulin product starting next year, following rivals Novo Nordisk (NOVOb.CO) and Eli Lilly and Co (LLY.N). The move comes as U.S. President Joe Biden has pushed to extend to most Americans the $35 cap on out-of-pocket insulin costs made available to Medicare recipients by the Inflation Reduction Act. Novo Nordisk and Eli Lilly bowed to political pressure earlier this month to make these life-sustaining diabetes treatments more affordable. Reporting by Patrick Wingrove in New York, Pratik Jain in Bengaluru; Editing by Maju SamuelOur Standards: The Thomson Reuters Trust Principles.

☆ Sanofi to cut US price of its most-prescribed insulin by 78%
▼ + stars: | 2023-03-16 | by ( Patrick Wingrove | ) www.reuters.com time to read: +3 min

In addition to Lantus, Sanofi said it will cut by 70% the list price for its fast-acting insulin, Apidra. The branded list price of Lantus is $438.07 for the pre-filled pens and $292.07 for a 10 ml vial. Rival Novo Nordisk on Tuesday said it would cut U.S. list prices for several insulin products by up to 75% next year. That followed Lilly's March 2 decision to cut list prices by 70% for Humalog and Humulin, its most commonly prescribed insulin products. Most Americans with insurance do not regularly pay list price for insulin, but they may have an insurance co-pay based on the drug's list price or pay full price up to a certain amount of money spent.

☆ Facing political pressure, Sanofi follows Eli Lilly and Novo Nordisk in slashing insulin prices
▼ + stars: | 2023-03-16 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Sanofi already offers a $35 monthly cap on insulin for uninsured diabetes patients. The company is the last major insulin manufacturer to try to head off government efforts to cap monthly costs by announcing its own steep price cuts for the lifesaving hormone. Eli Lilly and Novo Nordisk made similar sweeping cuts earlier this month after years of political pressure and public outrage over the high costs of diabetes care. President Joe Biden's Inflation Reduction Act capped monthly insulin costs for Medicare beneficiaries at $35, but it did not provide protection to diabetes patients who are covered by private insurance. Approximately 8.4 million diabetes patients rely on insulin, the American Diabetes Association said.

Although insulin list prices are high in the U.S., drugmakers typically pay substantial rebates to private insurers and government programs, resulting in lower prices for most Americans with insurance. U.S.-listed Novo Nordisk shares rose as much as 1.7% to $142.95, while Denmark-listed shares closed marginally higher on Tuesday. Eli Lilly shares were down slightly. "I think it is a relatively natural consequence of what we have seen their competitor Eli Lilly do. Eli Lilly, Sanofi and Novo Nordisk make up 90% of the U.S. market for insulin.

☆ Novo Nordisk joins Lilly in plans to slash U.S. insulin prices
▼ + stars: | 2023-03-14 | by ( ) www.reuters.com time to read: +1 min

March 14 (Reuters) - Novo Nordisk (NOVOb.CO) said on Tuesday it would cut U.S. list prices for several insulin drugs by up to 75% next year, joining rival Eli Lilly as drugmakers come under pressure for high prices of the life-sustaining treatment. The moves follow President Joe Biden's Inflation Reduction Act last year that capped insulin prices for Medicare recipients at $35 per month, but that does not extend to patients without insurance. Novo will reduce the list price of its NovoLog insulin by 75%, and for Novolin and Levemir by 65%. The company also said it would reduce the list price of unbranded insulin products to match lowered price of respective branded insulin products. Eli Lilly and Co (LLY.N) said earlier this month that it would cut the list prices for its most commonly prescribed insulin products by 70% from the fourth quarter of this year.

☆ Novo Nordisk to slash U.S. insulin prices by up to 75%, following move by Eli Lilly
▼ + stars: | 2023-03-14 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Novo Nordisk Inc. NovoLog brand insulin pens are arranged for a photograph in the Brooklyn borough of New York, U.S., on Friday, April 5, 2019. Novo Nordisk, one of the world's biggest insulin makers, will cut the list price of its NovoLog insulin by 75% and the prices for Levemir and Novolin by 65%, the company said in a press release. NovoLog's list price will fall to $139.71 from $558.83 for a pack of five injection pens. The company also said it plans to reduce the list price of its unbranded insulin products to match the lowered price of each respective branded insulin. Novo Nordisk, Lilly and Sanofi control over 90% of the global insulin market.

March 13 (Reuters) - France's Sanofi SA (SASY.PA) on Monday agreed to acquire Provention Bio Inc <PRVB.O> for $2.9 billion to bolster its work on a U.S.-approved type 1 diabetes therapy and strengthen its drug pipeline following development setbacks. The deal builds on an existing co-promotion agreement between the two companies, and would give the French drugmaker full ownership of the drug, Tzield, Sanofi said, adding it expects to complete the acquisition in the second quarter of 2023. While growth in asthma and eczema drug Dupixent is boosting Sanofi's sales, investors have criticised its drug development pipeline as weak. Sanofi, the maker of long acting insulin products Toujeo and Lantus for type 2 diabetes, in 2019 quit further type 2 diabetes drug development. Chief Executive Officer Paul Hudson said last month the company saw great promise in type 1 diabetes drug development and reaffirmed his commitment to steer clear of further work on type 2 diabetes and obesity.

☆ France's Sanofi to acquire US-based Provention Bio for $2.9 bln
▼ + stars: | 2023-03-13 | by ( Dina Kartit | ) www.reuters.com time to read: +1 min

March 13 (Reuters) - France's Sanofi (SASY.PA) said on Monday it has entered into a deal to acquire U.S.-based biopharmaceutical company Provention Bio in a transaction worth $2.9 billion, or $25.00 per share in cash. This transaction builds on an existing co-promotion deal between Sanofi and Provention Bio to provide TZIELD to patients in need, said the French firm. "Provention Bio also brings certain pipeline assets in early development in immune-mediated diseases," added the group. Sanofi said it expects to complete the acquisition in the second quarter of 2023. Reporting by Dina Kartit; Editing by Kim CoghillOur Standards: The Thomson Reuters Trust Principles.

☆ Stocks making the biggest moves midday: First Republic Bank, Moderna, Newmont, Illumina and more
▼ + stars: | 2023-03-13 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

REUTERS/Mike SegarCheck out the companies making the biggest moves midday:Regional banks —Shares of regional banks plummeted following the collapse of Silicon Valley Bank and Signature Bank. Citi , Bank of America , Goldman Sachs — Shares of major banks also saw losses after the closure of the Silicon Valley Bank and Signature Bank. Moderna — The biotechnology company's shares gained nearly 6% after TD Cowen upgraded the stock to outperform from market perform. Spot gold passed the key level of $1,900 as investors bet the Federal Reserve may tone down rate hikes on the heels of Silicon Valley Bank's collapse. Over the weekend, NBC News reported that the e-commerce company warned sellers that the collapse of Silicon Valley Bank is causing delays in processing payments.

☆ Merck's drug boosts exercise capacity in pulmonary hypertension patients
▼ + stars: | 2023-03-06 | by ( Khushi Mandowara | ) www.reuters.com time to read: +2 min

Sotatercept, combined with a background therapy, helped patients with pulmonary arterial hypertension to walk about 40.8 meters more in six minutes. J.P. Morgan analyst Chris Schott said the data exceeded the brokerage's expectations and "should confirm the drug as go-to add-on therapy" for pulmonary arterial hypertension. Schott forecast peak sales of $3 billion to $4 billion for the drug. In October, Merck said sotatercept had met the main goal of a late-stage study, but did not release the full data. Reporting by Khushi Mandowara and Pratik Jain in Bengaluru; Editing by Arun Koyyur and Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.

Search resuls for: "sanofi"

25 mentions found